tandem C-terminal alpha-synuclein vaccine

The tandem C-terminal alpha-synuclein vaccine is an investigational **active immunotherapy** being developed by Prothena for the potential treatment and prevention of **Parkinson's disease** and other **synucleinopathies**. It is a **peptide conjugate vaccine** composed of tandem C-terminal alpha-synuclein peptide epitopes conjugated to **CRM197** and administered with **QS21** adjuvant in preclinical studies. The intended mechanism is to induce endogenous antibodies against pathogenic C-terminal epitopes of alpha-synuclein, thereby promoting binding to pathological alpha-synuclein inclusions and inhibiting cellular uptake and spread of soluble or aggregated alpha-synuclein species. Publicly available information appears limited to preclinical conference and company disclosures, with no clearly identified clinical-stage program name for this exact tandem C-terminal construct.

Other names

tandem C-terminal alpha-synuclein vaccineC-terminal alpha-synuclein vaccineC-terminal/C-terminal tandem peptide-based alpha-synuclein vaccine